Professor Hiddo L. Heerspink
Co-Director, Better Treatments Program
Hiddo Lambers Heerspink is the Co-Director of the Better Treatments Program at the George Institute for Global Health.
He is also Professor of Clinical Trials and Personalized Medicine and a clinical trialist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen and visiting professor at the University of New South Wales in Sydney. He studied pharmacy at the University of Groningen and subsequently received his PhD from the University Medical Center Groningen. He worked as a Postdoctoral Fellow at The George Institute for Global Health, Sydney, Australia, where he investigated the effects of blood pressure-lowering regimens on renal and cardiovascular outcomes in patients with chronic kidney disease.
Professor Lambers Heerspink’s research interests focus on optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular diseases in patients with diabetes with a specific focus on personalized medicine. He leads and participates in clinical trials focused on renal and cardiovascular complications of type 2 diabetes. His main expertise includes clinical trial design and personalized medicine as well as methodological aspects and statistical analyses of clinical trials.
Professor L. Heerspink has received a VENI and VIDI Award from the Netherlands Organisation of Scientific Research, the Young Investigator Research Award from the European Foundation for the Study of Diabetes, the Harry Keen award from the European Association for the study of Diabetes and various personal grants from the Dutch Government and European Foundation to explore determinants of individual treatment response and develop strategies to improve the treatment for patients with type 2 diabetes and kidney complications. He is an editorial board member of the Clinical Journal of the American Society of Nephrology and served as guest editor for the scientific journals Diabetes Obesity & Metabolism and Nephrology Dialysis Transplantation. He has authored and co-authored over 250 peer-reviewed publications. Prof L. Heerspink is a consultant and has received honoraria from AbbVie, AstraZeneca, Boehringer Ingelheim, CSL Pharma, Janssen, Fresenius, Gilead Sciences, Merck, Mitsubishi Tanabe, Mundi Pharma and Retrophin.